At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA, from May 30 to June 3, the results of the Phase Ib/II clinical study of 9MW2821 in combination with ...

RVPH Open Label Extension Key Opinion Leader Event Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) held a key opinion ...

An analysis of the CALLA study shows that ctDNA is detected an average of 5.5 months before radiographic progression.

Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control ...

The drug, Mazdutide, is the world's first and currently only GCG/GLP-1 dual receptor agonist targeting both weight loss and ...

There are 182 clinical trials for Alzheimer’s treatments under way in 2025—an 11% increase on the previous year—testing 138 ...

Despite positive results from a Phase I/II trial of its investigational pandemic influenza vaccine, mRNA-1018, Moderna’s ...

For people diagnosed with macular telangiectasia type 2 (MacTel)—a rare and slowly progressing retinal disease—there have ...

Innovation in clinical diagnostics is accelerating, with breakthroughs that promise to make testing more precise, less invasive and more accessible. These advancements are expected not only to benefit ...

Highlights from the 2025 Global Equine Endocrinology Symposium included never-before-presented study results on insulin ...

Several oral abstracts presented at the American Society of Clinical Oncology’s annual meeting highlight ongoing research of Keytruda, Opdivo, Tecentriq and more in skin cancer.

Detection of cancer before a clinical diagnosis could give patients and caregivers more time for intervention and may lead to ...